MedPath

JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMET L.L.C.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Study of the Efficacy and Safety of Risperidone in the Prevention of Relapse in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders

Phase 3
Completed
Conditions
Attention Deficit and Disruptive Behavior Disorders
First Posted Date
2005-10-12
Last Posted Date
2011-06-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
375
Registration Number
NCT00236444

A Study of the Effectiveness and Safety of Topiramate Compared With a Standard Therapy in Patients Newly Diagnosed With Epilepsy

Phase 3
Completed
Conditions
Epilepsy
Seizures
First Posted Date
2005-10-12
Last Posted Date
2011-06-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
865
Registration Number
NCT00236717

A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil.

Phase 3
Completed
Conditions
Contraception
Female Contraception
First Posted Date
2005-10-12
Last Posted Date
2011-06-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
1494
Registration Number
NCT00236795

A Study of the Efficacy and Safety of Topiramate in Epilepsy Patients With Primary Generalized Tonic-clonic Seizures

Phase 3
Completed
Conditions
Epilepsy
Seizures
First Posted Date
2005-10-12
Last Posted Date
2011-06-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
80
Registration Number
NCT00236418

A Long Term Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia

Phase 3
Completed
Conditions
Schizophrenia
First Posted Date
2005-10-12
Last Posted Date
2011-06-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
100
Registration Number
NCT00236587

A Study of the Efficacy and Safety of Topiramate in the Treatment of Patients With Epilepsy.

Phase 2
Completed
Conditions
Epilepsy
Epilepsies, Partial
Seizures
First Posted Date
2005-10-12
Last Posted Date
2011-06-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
60
Registration Number
NCT00236847

A Study of the Efficacy and Safety of Topiramate as an add-on Therapy in the Treatment of Epilepsy Patients With Lennox-Gastaut Syndrome

Phase 3
Completed
Conditions
Epilepsy
Seizures
First Posted Date
2005-10-12
Last Posted Date
2011-06-03
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
100
Registration Number
NCT00236756

A Study of the Safety of Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior Disorders

Phase 3
Completed
Conditions
Disruptive Behavior Disorder
First Posted Date
2005-10-12
Last Posted Date
2011-06-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
232
Registration Number
NCT00236470

A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity

Phase 2
Completed
Conditions
Obesity
First Posted Date
2005-10-12
Last Posted Date
2010-12-03
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
385
Registration Number
NCT00236613

A Study of the Efficacy and Safety of Tramadol HCl/Acetaminophen, Hydrocodone Bitartrate/Acetaminophen and Placebo in Patients With Pain From an Ankle Sprain With a Partial Torn Ligament

Phase 3
Completed
Conditions
Sprains and Strains
Pain
First Posted Date
2005-10-12
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
603
Registration Number
NCT00236535
© Copyright 2025. All Rights Reserved by MedPath